36 results on '"Lübbert, M"'
Search Results
2. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
3. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
4. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
5. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
6. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED (ND) ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS
7. Topic: AS02-Epidemiology
8. Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation
9. Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes
10. 120 RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q)
11. 11 A panel of patient derived xenograft models of different haematological malignancies suitable for preclinical drug screening campaigns
12. O-022 Clinical features, treatment and prognosis in patients with MDS and monosomy 7
13. O-023 Did the prognosis of MDS patients improve during the last 30 years?
14. P-313 Response and progression rate of patients with primary MDS and isolated del(5q), IPSS low/int1 under treatment with lenalidomide
15. P-316 TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q) treated with lenalidomide: Results from the German Le-Mon-5 trial
16. P-277 Decitabine vs. best supportive care in elderly higher-risk MDS patients with or without monosomal karyotypes: EORTC-LG/GMDS-SG phase III trial 06011
17. P-111 Time changes in predictive power of MDS prognostic scores – Effects on revised scores such as the IPSS-R, impact of age
18. 119 2011-update and overview of data in the German-Austrian-Suisse MDS registry (D-A-CH MDS registry)
19. 347 Successful treatment of transfusional iron overload in MDS patients with deferasirox as indicated by Liver-MRI: A German, multi-center trial
20. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes
21. P028 Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q)
22. C005 Prognostic impact of the proportion of aberrant metaphases in patients with a primary myelodysplastic syndrome
23. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
24. PHM20 VALUE OF TRANSFUSION-FREE LIVING IN MDS: RESULTS OF HEALTH UTILITY INTERVIEWS WITH MDS PATIENTS
25. P.11 Multidimensional geriatric assessment in elderly patients with MDS/AML
26. OP21 Epigenetic therapy in the biological continuum of MDS and AML
27. C013 The influence of therapeutic strategies on survival in distinct cytogenetic subgroups – A collaborative study based on 3860 patients with MDS
28. P120 The development of a frailty index for elderly patients with MDS
29. P122 Value of transfusion-free living in myelodysplastic syndromes (MDS): results of health utility interviews with patients
30. Targets of epigenetic therapy – Gene reactivation as a novel approach in MDS treatment
31. 8 Geriatric assessment: a prospective study in older patients with AML and high-risk MDS
32. Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia
33. Differentiation associated modulation of the cytokine and chemokine expression pattern in human myeloid cell lines
34. 175 Low dose 5-AZA-′2-deoxycytidine in eldery patients with high risk MDS
35. Control of tetrahydrobiopterin synthesis in T lymphocytes by synergistic action of interferon-gamma and interleukin-2.
36. Myeloid cell lines: Tools for studying differentiation of normal and abnormal hematopoietic cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.